WP1 Coordination, management, and impact assessment (Lead: SVA)

• Coordinate and manage the project, including scientific, technological and administrative oversight
• Guarantee the successful progress of the project within the agreed time, cost and quality limits
• Foster collaboration and international cooperation
• Assess the EVH Project impact

WP2 Dissemination, communication, training and stakeholder engagement (Lead: SVA; All Partners involved)

• Establish effective communication among the consortium Partners
• Establish and implement effective dissemination and communication activities to maximise the project impact
• Establish an appropriate dissemination strategy for ensuring sustainability and long-term impact
• Communicate to the multiple audiences (stakeholders, policy makers and public) in a strategic and effective manner

WP3 Data management, AI (Lead: DZIF; Partners involved: SVA, UMR, HMGU, HZI, IP)

• Develop robust and resilient data infrastructures that can respond adaptively to the specific challenges of a pandemic phase
• Create a User Portal with a dashboard that connects the data streams generated in the consortium with the consortium members and decision-makers according to current needs
• Ensure fair access to data, documents, and tools and guarantee easy retrieval of data elements generated in the consortium
• Increase interoperability between trials, pandemic preparedness and exploratory biomarker identification and validation across trials
• Produce the EVH Data Management plan

WP16 Industry, IPRs, TT (Lead: DZIF; Partners involved: SVA, UMR, ZEPAI, FBS)

• Create a transparent public-private partnership (PPP) to prepare accelerated development in the event of pandemics
• Create a flexible instrument for rapid and flexible inclusion of Small and medium-sized enterprises (SMEs) in particular small biotechs with high innovation potential
• Build a network to foster collaboration between the Contract Research Organizations (CROs), Contract Development and Manufacturing Organizations (CDMOs), public research institutions and the private R&D and manufacturers
• Implement an instrument for gap analysis to identify missing capacities, skills and expertise as a fundament for PPP development
• Define the legal and intellectual property (IPr) framework to ensure rapid access to technologies and data in the event of a pandemic
• Prepare technology transfers (TTs) for mass production, sharing knowledge, methods, and tools from research and development teams to manufacturing partners

WP17 Vaccine readiness plans for Europe (Lead: SVA; Partners involved: UMR, ZEPAI, UoA, ULB, LUMC, FBS, IP, NIPH, Pasteur Network).

• Agree on and define at EU level standardised procedures and protocols for rapid decision making and implementation during health emergencies including a set public health-relevant prototype vaccines, scalable technologies and processes to anticipate future pandemics
• Development of EU epidemic and epidemic vaccines readiness plan
• Coordinate the multiple EU initiatives and stakeholders at EU to ensure a strategic autonomy against new pandemic threat: substantial manufacturing capacities in the EU, paired with the best research and development capacities, swift clinical trial networks and fast and non-controversial regulatory processes
• Integrate of dispersed efforts into one single targeted workstream to design, develop, and enable manufacturing of candidate vaccines (or antibodies) for preventive or therapeutic purposes
• Test and communicate the method for accelerating vaccine and H-mAbs development and availability in real conditions
• Develop a sustainability plan to ensure the long-term sustainability of EVH